Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study
Middleton MR. et al, (2019), ANNALS OF ONCOLOGY, 30
Identification of transcriptomic markers predictive of clonal response to checkpoint inhibitor treatment
Watson RA. et al, (2019), EUROPEAN JOURNAL OF IMMUNOLOGY, 49, 1744 - 1745
Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Dalle S. et al, (2019), ANNALS OF ONCOLOGY, 30
Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis
Sasson SC. et al, (2019), ANNALS OF ONCOLOGY, 30, 530 - 530
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
Peris K. et al, (2019), Eur J Cancer, 118, 10 - 34
Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs)
Fogarty GB. et al, (2019), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 105, S139 - S140
Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes.
de Santiago I. et al, (2019), Int J Cancer, 145, 1125 - 1137
Adjuvant whole brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicentre, randomized phase 3 trial
MIDDLETON M. et al, (2019), Journal of Clinical Oncology
The T cell architecture of pancreatic ductal adenocarcinoma.
Sivakumar S. et al, (2019), Annals of oncology : official journal of the European Society for Medical Oncology, 30 Suppl 4, iv64 - iv64
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Andtbacka RHI. et al, (2019), J Immunother Cancer, 7
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).
Lebbe C. et al, (2019), Eur J Cancer, 114, 117 - 127
IMMUNOTHERAPY-RELATED GASTRITIS IN A TERTIARY ONCOLOGY CENTRE
Cheung V. et al, (2019), GUT, 68, A147 - A148
An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).
Mandala M. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
Middleton MR. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Pharmacodynamic effect of IMCgp100 (TCR CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.
Middleton MR. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).
Fogarty G. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.
Milhem MM. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).
Taylor F. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37